Pharmazz wins FDA Orphan Drug Designation for sovateltide in NHIE

Pharmazz, Inc. has received Orphan Drug Designation (ODD) from the US Food and Drug Administration for sovateltide, its investigational endothelin-B receptor agonist, in neonatal hypoxic-ischaemic encephalopathy (NHIE). The designation, granted by the FDA's Office of Orphan Products Development, opens a set of regulatory and financial incentives for the Willowbrook, Illinois-based biopharmaceutical company as it works to advance sovateltide into clinical development for the condition.

NHIE arises when the newborn brain is deprived of oxygen and blood flow around the time of birth, causing injury that can result in cerebral palsy, epilepsy, cognitive impairment, or death. Existing therapeutic options are limited, with therapeutic hypothermia the only widely adopted standard of care. Pharmazz positions sovateltide as acting through selective endothelin-B receptor agonism to promote neural regeneration, neurovascular repair, and neuroprotection, a mechanism the company describes as distinct from current approaches.

Regulatory and commercial implications

Orphan Drug Designation confers several material advantages under the Orphan Drug Act for conditions affecting fewer than 200,000 patients in the United States. These include tax credits for qualified clinical testing expenditure, exemption from prescription drug user fees, and, critically, up to seven years of US market exclusivity following regulatory approval in the designated indication. For a company at Pharmazz's stage, the fee waiver and tax credit provisions can meaningfully reduce the cost of early-stage development.

Anil Gulati, chairman and chief executive of Pharmazz, said the designation marks an important milestone in the company's mission to address severe neurovascular conditions with high unmet medical need, adding that sovateltide's mechanism offers "strong potential to improve clinical outcomes for these vulnerable patients."

Stroke programme context

Sovateltide is simultaneously advancing in a broader ischaemic stroke programme. The Phase 3 RESPECT-ETB trial, registered as NCT05691244 and enrolling 514 patients across 57 sites in the US, Germany, Spain, and the UK, is evaluating sovateltide, branded as Tycamzzi, in acute ischaemic stroke. Pharmazz also has a Phase 4 trial under way and will present five datasets at the 18th World Stroke Congress in Seoul in late October 2026, including a meta-analysis of stroke efficacy and safety data and an interim Phase 4 analysis.

The NHIE designation is therefore strategically additive rather than pivotal; it extends the addressable indication set for the same molecule rather than representing a standalone programme with its own late-stage data.

Market landscape

The NHIE field remains relatively uncrowded at the late clinical stage, reflecting the difficulty of conducting neonatal trials rather than a lack of interest. A number of academic groups and small biotechs have explored neuroprotective agents in perinatal asphyxia, but none has yet reached regulatory approval specifically for NHIE in the US. That competitive whitespace, combined with the ODD incentives, gives Pharmazz a credible basis to attract development partnerships or grant funding to support IND-enabling work in the neonatal indication.

Investors will be watching for a defined clinical timeline and study design for the NHIE programme, as well as forthcoming stroke data from the World Stroke Congress presentations, which will provide the most substantive near-term read on sovateltide's clinical profile.